阿托伐他汀和氟伐他汀调节血脂异常临床效果的Meta分析

发布时间：2018-08-20 12:49

【摘要】：目的综合分析阿托伐他汀和氟伐他汀调节血脂异常的疗效、安全性和经济学效益。方法计算机检索Cochrane图书馆、PubMed、Medline、Embase、Wiley、Springer数据库,相关期刊论文(CNKI)、万方数据库(Wanfang)、中文科技期刊数据库(VIP),检索时间从建库至2016年6月。筛选阿托伐他汀和氟伐他汀调节血脂异常的临床随机对照研究(RCT),由两位研究者进行独立的文献评价和交叉核对,对文献报道的治疗前后高密度脂蛋白胆固醇((HDL-C)、低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)和总胆固醇(TC)等指标的变化进行Meta分析,并进行经济学评价。结果最终纳入7篇文献,服用氟伐他汀者684例,服用阿托伐他汀者2 208例。阿托伐他汀降低LDL-C、TC和TG水平的作用明显优于氟伐他汀,差异均有统计学意义(Z=23.63、23.32、5.50,P0.000 01);而对HDL-C水平的影响两种药物比较,差异无统计学意义(Z=1.01,P=0.31)。阿托伐他汀提高疗效增加总费用低于氟伐他汀。结论阿托伐他汀调节LDL-C、TC、TG的作用较氟伐他汀更强,而升高HDL-C的作用二者无明显差异,且阿托伐他汀经济学效应更具优势。
[Abstract]:Objective to analyze the efficacy, safety and economic benefit of Atto vastatin and fluvastatin in regulating dyslipidemia. Methods the Cochrane library was searched by computer, and the (CNKI), Wanfang database, (Wanfang), Chinese sci-tech journal database (VIP), was searched by computer from the time from the establishment of the database to June 2016, and the Chinese journal full-text database, (CNKI), Wanfang database, was used to retrieve the database. Screening of Atto and fluvastatin for regulating dyslipidemia; (RCT), was evaluated and cross-checked by two independent researchers. The changes of high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglyceride (TG) and total cholesterol (TC) before and after treatment were analyzed by Meta and evaluated by economics. Results among the 7 articles, 684 cases were treated with fluvastatin and 2 208 cases with Atto vastatin. The effect of Atto vastatin on decreasing LDL-CnTC and TG levels was significantly higher than that of fluvastatin (P 0.00001), but there was no significant difference in the effect of Vastatin on the level of LDL-Con and TG (ZH1.01 P0.31). The total cost of increasing the efficacy of Atto vastatin was lower than that of fluvastatin. Conclusion the effect of Atto vastatin on the regulation of TG in LDL-CfT is stronger than that on fluvastatin, but there is no significant difference between them in increasing HDL-C, and the economic effect of Atto vastatin is superior.
【作者单位】：重庆医科大学附属第二医院药学部;
【基金】：国家自然科学青年基金资助项目(81402937) 重庆市卫生计生委面上项目(2017MSXM027,2010-2-163)
【分类号】：R589.2

【相似文献】